Iodixanol
Visipaque (iodixanol) is an unknown pharmaceutical. Iodixanol was first approved as Visipaque 270 on 1996-03-22.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Visipaque (generic drugs available since 2022-05-19)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| visipaque | New Drug Application | 2023-05-08 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
IODIXANOL, IODIXANOL, HENGRUI PHARMA | |||
| 2023-01-09 | CGT | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
109 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic granulomatous disease | D006105 | EFO_0000338 | D71 | 1 | — | — | 2 | 1 | 4 |
| Wiskott-aldrich syndrome | D014923 | D82.0 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Friedreich ataxia | D005621 | Orphanet_95 | G11.11 | — | 3 | 3 | — | — | 6 |
| Pulmonary fibrosis | D011658 | J84.10 | 1 | 1 | 3 | — | — | 5 | |
| Melanoma | D008545 | 2 | 1 | 1 | — | — | 4 | ||
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | 1 | 3 | — | — | 4 |
| Osteopetrosis | D010022 | Q78.2 | — | 2 | 1 | — | 1 | 4 | |
| Idiopathic pulmonary fibrosis | D054990 | J84.112 | — | 1 | 3 | — | — | 4 | |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 1 | 1 | — | — | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 2 | 1 | — | — | 3 |
| Candidemia | D058387 | EFO_1001282 | — | 1 | 1 | — | — | 2 | |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 1 | 1 | — | — | 2 |
Show 9 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 3 | 3 | — | — | 1 | 6 |
| Hiv | D006678 | O98.7 | 2 | 2 | — | — | 2 | 4 | |
| Neoplasms | D009369 | C80 | 2 | 2 | — | — | — | 4 | |
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | 1 | 2 | — | — | 2 | 4 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | 3 | — | — | — | 3 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | 1 | — | — | 2 | 3 |
| Mycobacterium avium-intracellulare infection | D015270 | EFO_0007386 | 1 | 1 | — | — | — | 2 | |
| Colorectal neoplasms | D015179 | — | 2 | — | — | — | 2 | ||
| Fallopian tube neoplasms | D005185 | 1 | 1 | — | — | — | 2 | ||
| Synovial sarcoma | D013584 | 1 | 1 | — | — | — | 2 |
Show 41 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | D46 | 2 | — | — | — | — | 2 | |
| Neuroblastoma | D009447 | EFO_0000621 | 1 | — | — | — | — | 1 | |
| Osteosarcoma | D012516 | 1 | — | — | — | — | 1 | ||
| Ewing sarcoma | D012512 | EFO_0000173 | 1 | — | — | — | — | 1 | |
| Rhabdomyosarcoma | D012208 | 1 | — | — | — | — | 1 | ||
| Myeloid leukemia | D007951 | C92 | 1 | — | — | — | — | 1 | |
| Xerostomia | D014987 | K11.7 | 1 | — | — | — | — | 1 | |
| Glioblastoma | D005909 | EFO_0000515 | 1 | — | — | — | — | 1 | |
| Psoriasis | D011565 | EFO_0000676 | L40 | 1 | — | — | — | — | 1 |
| Ovarian epithelial carcinoma | D000077216 | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Latent tuberculosis | D055985 | Z22.7 | — | — | — | — | 3 | 3 | |
| Respiratory tract infections | D012141 | J06.9 | — | — | — | — | 3 | 3 | |
| Covid-19 | D000086382 | U07.1 | — | — | — | — | 1 | 1 | |
| Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | — | — | — | — | 1 | 1 |
| Viral pneumonia | D011024 | EFO_0007541 | J12.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | IODIXANOL |
| INN | iodixanol |
| Description | Iodixanol is a dimeric, non-ionic, water-soluble, radiographic contrast agent, used particularly in coronary angiography. It has a role as a radioopaque medium. |
| Classification | Small molecule |
| Drug class | iodine-containing contrast media |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I |
Identifiers
| PDB | — |
| CAS-ID | 92339-11-2 |
| RxCUI | 27729 |
| ChEMBL ID | CHEMBL1200507 |
| ChEBI ID | 31705 |
| PubChem CID | 3724 |
| DrugBank | DB01249 |
| UNII ID | HW8W27HTXX (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,871 documents
View more details
Safety
Black-box Warning
Black-box warning for: Visipaque
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,392 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more